• Network expansion: Thyrocare grew its franchise network from 2,700 in FY22 to 11,700, helping drive a 26% growth in pathology revenue alongside nearly 100% NABL accreditation across its lab network.
• Affordable pricing strategy: Management is unconcerned by lower realization (test per patient grew 9.6% vs. revenue per patient at 6.8%), explaining that fixed patient collection costs allow high-volume, lower-priced add-on tests to flow directly to the bottom line.
• Specialty diagnostics outlook: Having entered allergy testing and genomics, the company aims to scale its specialty diagnostics contribution from near 0% to 15–20% of revenue over the next 3 to 5 years, aligning with peer levels.
• Revenue growth guidance: Management is maintaining its conservative mid-to-high teens growth guidance for now, choosing to assess performance after Q2—the peak monsoon diagnostic season—and the close of H1 before considering revisions.